Companies hunting for new ways to tackle cancer to Alzheimer's raised $6.3 billion going public in 2018 - here are the 10 biggest deals of the year

IPO Proceeds: $144 million

Date of IPO: March 28

Homology Medicines wants to treat genetic diseases using viruses instead of CRISPR. Its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) is designed to deliver genetic medicines through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders.

Get the latest Homology Medicines stock price here.

IPO Proceeds: $150 million

Date of IPO: June 22

Autolus Therapeutics develops CAR-T cell immunotherapies for blood and solid tumor cancers. It expects to report proof-of-concept data from five programs in 2019.

Get the latest Autolus Therapeutics stock quote here.

IPO Proceeds: $152.6 million

Date of IPO: May 24

Kiniska Pharmaceuticals develops drugs targeting autoinflammatory and autoimmune disease. Its atopic dermatisis drug KPL-716 showed positive results in a phase I trial.

Get the latest Kiniksa Pharmaceuticals stock quote here.

IPO Proceeds: $200 million

Date of IPO: October 31

Orchard Therapeutics is developing gene therapies for rare diseases, including a treatment for "bubble boy" disease which it licensed from GlaxoSmithKline.

Get the latest Orchard stock price here.

IPO Proceeds: $207.8 million

Date of IPO: April 19

MorphoSys is developing antibodies for cancer, Alzheimer's Disease, infectious diseases, cardiovascular diseases, and inflammation. MorphoSys has collaborated with partners and developed more than 100 product candidates, of which 29 are currently in clinical development.

Get the latest on MorphoSys AG's stock here.

IPO Proceeds: $222.3 million

Date of IPO: June 28

Tricida is developing therapeutics to treat renal, metabolic and cardiovascular disease. Its lead product is an oral drug designed to treat metabolic acidosis in patients with chronic kidney disease.

Get the latest on Tricida's stock here.

IPO Proceeds: $241.1 million

Date of IPO: July 18

Rubius Therapeutics uses reprogrammed red blood cells to treat conditions like cancer. It's also developing enzyme replacement therapies for rare conditions where a person can't make a particular enzyme in their body. The Cambridge-based company recently opened a manufacturing facility in Smithfield, Rhode Island.

Get the latest Rubius Therapeutics stock price here.

IPO Proceeds: $324 million

Date of IPO: October 11

Allogene is developing less-personalized versions of CAR-T cell therapies using new cell therapies licensed in from Pfizer. As part of its deal, Allogene gets the rights to 16 preclinical CAR-T therapies, which includes treatments for both blood and solid-tumor cancers. The experimental treatments come out of a collaboration between Cellectis, a gene-editing company, and Pfizer.

Allogene hit the ground running, picking up more than $300 million in funding in April then turning around to raise $324 million in its public offering just a few months later in October.

Get the latest Allogene stock price here.

IPO Proceeds: $604 million

Date of IPO: December 7

Moderna is developing medical treatments based on messenger RNA, and the company is still in the early days of human trials for its treatments, which include cancer treatments as well as a vaccine for cytomegalovirus, or CMV. It currently holds the title of the largest IPO in biotech history.

Get the latest Moderna stock price here.